论文部分内容阅读
目的观察曲美他嗪对扩张型心肌病患者运动耐量及生活质量的影响。方法 26例扩张型心肌病患者随机分为治疗组14例和对照组12例,对照组给予血管紧张素转换酶抑制剂、利尿剂、洋地黄和β-受体阻滞剂等常规治疗,治疗组在对照组基础上给予曲美他嗪片20 mg/次,3次/d,口服。2组疗程均为3个月。比较2组治疗前、后6 min最大步行距离和明尼苏达心力衰竭生活质量调查表评分。结果 2组治疗后6 min最大步行距离较治疗前增加(P<0.01),MLHFQ评分较治疗前降低(P<0.01),治疗组改善优于对照组(P<0.05)。结论曲美他嗪可提高扩张型心肌病患者运动耐量,改善生活质量。
Objective To observe the effect of trimetazidine on exercise tolerance and quality of life in patients with dilated cardiomyopathy. Methods Twenty-six patients with dilated cardiomyopathy were randomly divided into treatment group (n = 14) and control group (n = 12). The control group was given conventional therapy such as angiotensin converting enzyme inhibitor, diuretic, digitalis and β-blockers On the basis of the control group, trimetazidine tablets were given 20 mg once daily for 3 times daily. The two groups were treated for 3 months. The maximal walking distance and the Minnesota Heart Failure Quality of Life Questionnaire score were compared between the two groups before and 6 months after treatment. Results The maximum walking distance at 6 min after treatment was significantly increased in both groups (P <0.01). The MLHFQ score was lower than that before treatment (P <0.01). The improvement in the treatment group was better than that in the control group (P <0.05). Conclusion Trimetazidine can improve exercise tolerance and improve quality of life in patients with dilated cardiomyopathy.